Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hologic/Cytyc Merger Combines Diverse Women’s Health Device Portfolios

This article was originally published in The Gray Sheet

Executive Summary

The combination of mammography device maker Hologic and cervical cancer test firm Cytyc will create a women's health powerhouse with $1.44 billion in combined annual revenues

You may also be interested in...



New Product Briefs

Hologic: Company expects to launch its new radiation therapy system by the end of the year, having secured FDA clearance Aug. 27, Hologic announced Sept. 1. MammoSite ML is a multi-lumen version of the firm's original, single-lumen MammoSite system, cleared in 2002. The accelerated partial breast irradiation (APBI) devices provide targeted breast cancer radiation therapy directly to the area where cancer is most likely to recur by inflating a balloon catheter containing radioactive material into the surgical cavity after the tumor is removed. The multi-lumen model allows oncologists to shift the radiation dose to the areas within the cavity that need it most, the firm explains. Hologic obtained the MammoSite technology when it bought Cytyc for $6.2 billion in 2007 (1"The Gray Sheet" May 28, 2007)

New Product Briefs

Hologic: Company expects to launch its new radiation therapy system by the end of the year, having secured FDA clearance Aug. 27, Hologic announced Sept. 1. MammoSite ML is a multi-lumen version of the firm's original, single-lumen MammoSite system, cleared in 2002. The accelerated partial breast irradiation (APBI) devices provide targeted breast cancer radiation therapy directly to the area where cancer is most likely to recur by inflating a balloon catheter containing radioactive material into the surgical cavity after the tumor is removed. The multi-lumen model allows oncologists to shift the radiation dose to the areas within the cavity that need it most, the firm explains. Hologic obtained the MammoSite technology when it bought Cytyc for $6.2 billion in 2007 (1"The Gray Sheet" May 28, 2007)

Research In Brief

G.I. Liner: GI Dynamics' EndoBarrier gastrointestinal liner significantly reduces average blood glucose levels in patients with type 2 diabetes, according to results of a three-month, 18-patient, sham-controlled pilot study presented at the First World Congress on Interventional Therapies for Type 2 Diabetes in New York Sept. 16. The data, presented by Lee Kaplan, M.D./Ph.D, Harvard Medical School, show that the 12 patients treated with EndoBarrier in the trial experienced a mean reduction in average blood glucose of 2.9% from a baseline of 8.9%, compared to a reduction of 0.76% from a baseline of 9% in the six patients in the sham control group. EndoBarrier is an endoscopically implantable barrier that creates a duodenal-jejunal bypass to prevent food from contacting the intestinal wall. Investigators believe the bypass reduces a patient's uptake of both nutrients and calories and creates a similar metabolic effect as Roux-en-Y gastric bypass surgery, which has been shown to promote weight loss and resolution of type 2 diabetes. The firm plans to launch a major trial of an enhanced version of EndoBarrier in 2009

Related Content

Latest News
See All
UsernamePublicRestriction

Register

MT024846

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel